Imelciment Antibody is a research-grade biosimilar monoclonal antibody. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.
Product Name:
Imelciment Antibody
SKU:
GXBS02321
Size:
100 µg, 1 mg
Antibody Type:
Monoclonal Antibody
Target:
Vixticibart
Isotype:
Immunoglobulin (H-gamma4_L-kappa)_G4hCH2CH3
Host Species:
Human
Reactivity:
Human
Applications:
ELISA, FCM, Functional assay, Research in vivo
Expression Host:
Mammalian cells
Synonyms:
Idiotypic, 2845128-03-0
Biological Activity:
Vixticibart specifically binds to human and monkey natriuretic peptide receptor 1 extracellular domain proteins, with no cross-reactivity to mouse natriuretic peptide receptor 1, natriuretic peptide receptor 2, or natriuretic peptide receptor 3, and does not interfere with atrial natriuretic peptide binding to human natriuretic peptide receptor 1 [1]. Vixticibart (10 -12 to 10 -6 M; under conditions supporting binding) dose-dependently binds to human and monkey natriuretic peptide receptor 1-expressing HEK293 cells, with enhanced binding in the presence of atrial natriuretic peptide or brain natriuretic peptide, and EC 50 values ranging from 2.27 to 5.69 nM [1]. Vixticibart (10 -15 to 10 -5 M) dose-dependently agonizes human and monkey natriuretic peptide receptor 1 in a calcium flux bioassay, with EC 50 values ranging from 42.5 to 82.2 nM, and achieves maximum activation comparable to natriuretic peptide ligands at high concentrations [1]. Vixticibart (10 -14 to 10 -5 M) dose-dependently activates human natriuretic peptide receptor 1 to induce cGMP accumulation in HEK293 cells, acts as a partial agonist relative to natriuretic peptide ligands, and shows enhanced activation in the presence of low concentrations of atrial natriuretic peptide or brain natriuretic peptide [1]. Vixticibart (molar excess; overnight at 4°C) binds to the N-terminal domain of human NPR1 dimers, stabilizing an active conformation in the presence of atrial natriuretic peptide and an active-like conformation in the absence of atrial natriuretic peptide, which drives downstream signaling [1]. Vixticibart (1-50 mg/kg; s.c.; single dose) induces a 10-15 mm Hg reduction in systolic blood pressure in normotensive NPR1 hu/hu mice, with dose-dependent duration of effect lasting up to 28 days for the 50 mg/kg dose [1]. Vixticibart (25 mg/kg; i.v.
Purity:
>95% as determined by SDS-PAGE.
Endotoxin Level:
< 10 EU/mg
Formulation:
0.01M PBS pH 7.4.
State of Matter:
Liquid
Regulatory Status:
For research use only. Not suitable for clinical or therapeutic use.
Product Preparation:
Protein A/G purified from cell culture supernatant.
Storage and Handling:
Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
